An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies With HRAS Mutations

Trial Profile

An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies With HRAS Mutations

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Tipifarnib (Primary)
  • Indications Head and neck cancer; Solid tumours; Squamous cell cancer; Thyroid cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Kura Oncology
  • Most Recent Events

    • 16 Oct 2017 According to a Kura Oncology media release, data will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017.
    • 11 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Aug 2018.
    • 11 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top